| (Values in U.S. Thousands) | Dec, 2021 | Dec, 2020 | Dec, 2019 | Dec, 2018 | Dec, 2017 |
| Sales | 183,980 | 149,600 | 123,860 | 63,550 | 54,520 |
| Sales Growth | +22.98% | +20.78% | +94.90% | +16.56% | +4.40% |
| Net Income | 46,290 | 56,200 | -2,030 | -6,520 | -16,740 |
| Net Income Growth | -17.63% | +2,868.47% | +68.87% | +61.05% | +31.22% |
Antares Pharma (ATRS)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
5.59 unch (unch) 05/23/22 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 5.59 unch (unch) -
for Mon, May 23rd, 2022
Antares Pharma, Inc. develops, commercializes and markets novel delivery solutions, including needle-free and mini-needle injector systems, gel technologies and transdermal products, which improve both the efficiency of drug therapies and the quality of life for patients. The Company currently distributes its needle-free injector systems for the delivery of insulin and growth hormone in over 20 countries and an estradiol transdermal patch for hormone replacement therapy.
Fiscal Year End Date: 12/31